Longboard Pharmaceuticals Announces Interim Results From 52-Week Open-Label Extension Of PACIFIC Study Evaluating Bexicaserin (LP352) In Participants With Developmental And Epileptic Encephalopathies

Author: Benzinga Newsdesk | June 10, 2024 09:03am

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%
Favorable safety and tolerability results observed
100% of participants who completed the PACIFIC Study entered the OLE
End of Phase 2 Meeting scheduled for this summer

Posted In: LBPH